These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21062262)

  • 1. Bioimaging for the monitoring of the in vivo distribution of infused mesenchymal stem cells in a mouse model of the graft-versus-host reaction.
    Joo SY; Cho KA; Jung YJ; Kim HS; Park SY; Choi YB; Hong KM; Woo SY; Seoh JY; Ryu KH
    Cell Biol Int; 2011 Apr; 35(4):417-21. PubMed ID: 21062262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory effects of mesenchymal stem cells involved in favoring type 2 T cell subsets.
    Lu X; Liu T; Gu L; Huang C; Zhu H; Meng W; Xi Y; Li S; Liu Y
    Transpl Immunol; 2009 Dec; 22(1-2):55-61. PubMed ID: 19695330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placenta-derived mesenchymal stem cells have an immunomodulatory effect that can control acute graft-versus-host disease in mice.
    Jang MJ; Kim HS; Lee HG; Kim GJ; Jeon HG; Shin HS; Chang SK; Hur GH; Chong SY; Oh D; Chung HM
    Acta Haematol; 2013; 129(4):197-206. PubMed ID: 23257958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCR4-transduced mesenchymal stem cells protect mice against graft-versus-host disease.
    Chen W; Li M; Li Z; Yan Z; Cheng H; Pan B; Cao J; Chen C; Zeng L; Xu K
    Immunol Lett; 2012 Apr; 143(2):161-9. PubMed ID: 22342854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inducible Costimulator Gene-Transduced Bone Marrow-Derived Mesenchymal Stem Cells Attenuate the Severity of Acute Graft-Versus-Host Disease in Mouse Models.
    Yang D; Wang LP; Zhou H; Cheng H; Bao XC; Xu S; Zhang WP; Wang JM
    Cell Transplant; 2015; 24(9):1717-31. PubMed ID: 25203502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced efficacy of mesenchymal stromal cells in preventing graft-versus-host disease in an in vivo model of haploidentical bone marrow transplant with leukemia.
    Oviedo A; Yañez R; Colmenero I; Aldea M; Rubio A; Bueren JA; Lamana ML
    Cell Transplant; 2013; 22(8):1381-94. PubMed ID: 23044223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
    Li Y; Guo K; Chen Y; Song Z; Li J; Deng L
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CM-DiI labeled mesenchymal stem cells homed to thymus inducing immune recovery of mice after haploidentical bone marrow transplantation.
    Hu KX; Wang MH; Fan C; Wang L; Guo M; Ai HS
    Int Immunopharmacol; 2011 Sep; 11(9):1265-70. PubMed ID: 21530684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal stem cells enhance the induction of mixed chimerism and tolerance to rat hind-limb allografts after bone marrow transplantation.
    Pan H; Zhao K; Wang L; Zheng Y; Zhang G; Mai H; Han Y; Yang L; Guo S
    J Surg Res; 2010 May; 160(2):315-24. PubMed ID: 19524257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of oral tolerance in bone marrow transplantation recipients suppresses graft-versus-host disease in a semiallogeneic mouse model.
    Nagler A; Ohana M; Alper R; Doviner V; Sherman Y; Rabbani E; Engelhardt D; Ilan Y
    Bone Marrow Transplant; 2003 Aug; 32(4):363-9. PubMed ID: 12900772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experiment study of efficacy on hematopoietic reconstitution and GVHD prophylaxis after mesenchymal cell infused by intra-bone marrow cavity or intravenous in rat BMT models].
    Huang K; Huang SL; Zhou DH; Cai Y; Zhang XC; Li Y
    Zhonghua Xue Ye Xue Za Zhi; 2007 Feb; 28(2):87-92. PubMed ID: 17650667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation.
    Prigozhina TB; Khitrin S; Elkin G; Eizik O; Morecki S; Slavin S
    Exp Hematol; 2008 Oct; 36(10):1370-6. PubMed ID: 18619727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?
    Hirshfeld E; Weiss L; Kasir J; Zeira M; Slavin S; Shapira MY
    Bone Marrow Transplant; 2006 Sep; 38(5):359-64. PubMed ID: 16862165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional and phenotypic alteration of intrasplenic lymphocytes affected by mesenchymal stem cells in a murine allosplenocyte transfusion model.
    Li H; Guo ZK; Li XS; Hou CM; Tang PH; Mao N
    Cell Transplant; 2007; 16(1):85-95. PubMed ID: 17436858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal stem cells administered after liver transplantation prevent acute graft-versus-host disease in rats.
    Xia X; Chen W; Ma T; Xu G; Liu H; Liang C; Bai X; Zhang Y; He Y; Liang T
    Liver Transpl; 2012 Jun; 18(6):696-706. PubMed ID: 22344929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
    Tian Y; Deng YB; Huang YJ; Wang Y
    Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice.
    Chen C; Cao J; Zeng L; Li Y; Wang D; Xu K
    Transplant Proc; 2011 Jun; 43(5):2041-8. PubMed ID: 21693322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Xenoreactivity of human clonal mesenchymal stem cells in a major histocompatibility complex-matched allogeneic graft-versus-host disease mouse model.
    Jeon MS; Lim HJ; Yi TG; Im MW; Yoo HS; Choi JH; Choi EY; Song SU
    Cell Immunol; 2010; 261(1):57-63. PubMed ID: 20004369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.